Stoke Therapeutics (STOK) PT Lowered to $40 on Sharecount at BofA Securities Despite Monarch Trial Making Meaningful Progress
Tweet Send to a Friend
BofA Securities analyst Greg Harrison lowered the price target on Stoke Therapeutics (NASDAQ: STOK) to $40.00 (from $43.00) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
